IG Petrochemicals Ltd

Sell



Chemical| Plant Visit Note

November 2021

Positive

Maintaining leadership position in domestic PAN market

During our visit to IG Petrochemicals Ltd (IGPL) plant at Taloja (one of the largest capacity of PAN at a single location), we interacted with Mr. Pramod Bhandari (CFO). This plant is engineered with Technical collaboration with Lurgi Gmbh, Germany and designed on the low energy-based processes. IGPL is the largest manufacturer of Pthalic anhydride (PAN) and only manufacturer of Maleic anhydride in India. Post expansion IGPL currently produces around 2,22,110 MTPA of PAN, 7,660 MTPA of Maleic Anyhdride (MA) and 1,500 MTPA of benzoic acid and 8,400 MTPA of plasticizers at its Taloja complex.

Following are the key takeaways from plant visit

Strategically located

IG Petrochemicals has several advantages over its competitors that ensure it leads and dominates the PAN space in India. These advantages combine to create unique strengths that are difficult for competitors to replicate and create high entry barriers for new players. One of the critical success factors is location. An ideal location should be close to both the source of raw material as well as customers. The Company's plant is located at Taloja, about 50 kms. from Mumbai, the commercial capital of India. This location results in multiple advantages for the Company. On the supply side, the major source of raw material for the manufacture of PAN comes from the same region, creating compelling cost savings in transportation. On the demand side, more than 70% of PAN produced in India is consumed in western India. With 90% sales locally, the plant's location is just 50kms. from Mumbai enables the Company to be close to its customers. Moreover, the port of Mumbai is a gateway to all major export markets for the Company, ensuring quicker transit times for its products. Complementing an ideal location is the wise procurement strategy for Ortho-xylene (OX) - the single raw material required to manufacture PAN. Post the commissioning of PA4 plant, the company's integration across four PAN manufacturing units has resulted in a substantial reduction in the cost of conversion to about \$90/tn (vs \$140/tn-150/tn with a single PA1 plant) due to improved operating leverage which is aiding the company's profitability.

Only producer of MA in India

Due to the non-availability of key raw material such as N-Butane (a gas derivative) for manufacturing MA (Maleic anhydride), 90% of India's consumption of MA (~60,000-65,000MTPA) is currently met through imports (mainly from Malaysia, China and Taiwan. Food grade MA consists of half of the MA consumption in India, and the rest 50% is consumed in Non-food grade products (IGPL is into nonfood grade MA). IGPL uses wash water created from the manufacturing process of PA to recover MA and Benzoic acid (MA/PAN yield 0.03x). With less than 6% of the market share in the domestic market and being a sole manufacturer in India, IGPL believes there is enough opportunity to grow in the MA business. In FY21, MA generated INR572mn of annual sales with an EBITDA margin of 90%. Recent PA4 expansion results in additional wash water used to create more MA capacity for the Company (currently 7.660 MTPA), With higher MA capacity, IGPL is all set to grow its foothold in the MA business. Major applications of MA are in unsaturated polyester resin (UPR), spandex (elastics), insecticides, fungicides, water treatment and lubricant oil additives.

Foray into advanced plasticizer to provide scope for margin stability

IGPL also forayed into the downstream product by introducing speciality plasticizer DEP (Di-Ethyl Phthalate). The company commenced commercial production of DEP (in Nov 21) with a capacity of 8,400 MTPA with a 50% increasing possibility at a minimum Capex. Since the compound Relative Price Chart is a suitable solvent for many organic molecules, it is often used to bind cosmetics and fragrances (mainly incense sticks and attar). Domestic demand for DEP is 22,000 MTPA with almost the same in terms of supply. The company is planning to cross-sell this product to existing plasticizer clients since DEP carries a better margin (EBITDA ~20-25%) increase in contribution from this product to strengthen the overall margin of the company further.

Future outlook

Management is aspiring to achieve INR25bn topline by FY25. Moreover, they intend to diversify their product portfolios by getting into other downstream derivatives and other speciality chemicals with aiming to have 30% of its revenue from non-phthalic products.

Stock Rating

Sector Outlook

| BUY | HOLD | SELL |
|-------|------------|-------|
| | | |
| > 15% | -5% to 15% | < -5% |


| Stock | |
|--------------------|---------|
| CMP (INR) | 738 |
| Target Price (INR) | 691 |
| BSE code | 500199 |
| NSE Symbol | IGPL |
| Bloomberg | IGPL IN |
| Reuters | IGPT.BO |
| | |


| Key Data | |
|---------------------|------------|
| Nifty | 17,536 |
| 52WeekH/L(INR) | 1018 / 355 |
| O/s Shares (Mn) | 31 |
| Market Cap (INR bn) | 22.7 |
| Face Value (INR) | 10 |
| | |

Average volume

| 3 months | 1,62,980 |
|----------|----------|
| 6 months | 1,88,460 |
| 1 year | 1,35,700 |

Share Holding Pattern (%)







Research Analyst

Nikhil Shetty nikhilshetty@bpwealth.com 022-61596408



Phthalic Anhydride Consumption and Import trend (of Domestic market)







Source: Industry, BP Equities Research (estimates)

As per our calculation, In FY21 the Indian market consumed approximately 35,000 Mt per month of Phthalic anhydride and growing at a rate of about 6-8% per annum. There was an import of Phthalic anhydride of almost ~12,000 MT per month, which can be substituted by the local Manufacturers like IG Petrochemicals Ltd and M/s. Thirumalai Chemicals Ltd. More so with the fact that there is an anti-dumping duty imposed on most countries against imports into India. Thus, there is a huge opportunity going forward to increase the capacitates in India, thereby reducing the cost of production, which will make domestic players more competitive in India and the global markets.

MA import trend

Contribution from Non PAN products to reach 30% by FY25






Source: Company, Industry, BP Equities Research (estimates)

Capacity expansion to drive the next phase of growth

To meet growing demand and post faster absorption of recently commissioned capacity PA4 (utilization 90%), IGPL plans to set up a new plant through brownfield expansion in the same plant with the PAN capacity of 53,000 TPA (PA5), which increases its total capacity to 2,75,110 TPA by CY24. The total Capex outlay for this project is INR 3.45bn, with the duration proposed being 24-30 months. The demand for Phthalic Anhydride in the domestic market is expected to increase due to Govt. focus on Infrastructure spending and demand growth in downstream products like Paints, Plasticizers, Polyvinylchloride, Unsaturated polyester resins (UPR), etc., supported by strong GDP growth in India. As per our estimate, IGPL can generate FCF of INR 3.34bn over FY22-23 based on healthy operational performance. According to management, commercial production of Advanced Plasticizer (production capacity of 8,400 MTPA at Taloja) is started this week. We modeled INR 500mn incremental revenue from Advanced Plasticizer in FY22E with a better margin profile.

Revenue/EBITDA/PAT trend


Capacity Expansion & Strategies



Source: Company, BP Equities Research

PAN and OX price trend

Average PAN/Ox spread over FY10 to FY21: US\$215



Source: Industry, Note: Above PAN and OX prices are SE Asia prices


Source: BP Equities Research

Valuation and Outlook

IGPL continues to be a market leader in the domestic PAN industry with a strong clientele, healthy balance sheet, and expansion in value-added products (downstream speciality plasticizers). However, we could see some margin contraction in H2FY22e as stabilization of PAN/OX spread from elevated levels (H1FY22: \$200-\$250 vs Avg \$320 in FY21). Moreover, as IGPL is already operating at optimum utilization level, the following capacity addition is 24 to 30 months away (assuming no delay). Therefore, we expect a minimal scope for volume growth in FY23-24. Therefore, we maintain our Sell rating on the stock with a price target of INR 691 based on 12x FY23e earnings.

Key Risk: Adverse movement in PAN/OX spread

Production Process of Phthalic Anhydride and Maleic Anhydride



Source: Company

Key Customers



Source: Company



| | Profit & Loss | A/c | | | |
|-----------------------------|---------------|--------|--------|--------|--------|
| YE March (INR. Mn) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Revenue | 13,037 | 10,586 | 11,236 | 15,582 | 15,850 |
| Growth % | 13.9% | -18.8% | 6.1% | 38.7% | 1.7% |
| Total Revenue | 13,037 | 10,586 | 11,236 | 15,582 | 15,850 |
| Less: | | | | | |
| Raw Material Consumed | 9,128 | 8,172 | 6,514 | 10,603 | 10,749 |
| Employee Cost | 618 | 602 | 707 | 778 | 855 |
| Other Expenses | 1,064 | 1,096 | 1,029 | 1,427 | 1,451 |
| Total Operating Expenditure | 10,810 | 9,869 | 8,250 | 12,807 | 13,056 |
| EBITDA | 2,227 | 717 | 2,986 | 2,775 | 2,794 |
| Growth % | -16.7% | -67.8% | 316.7% | -7.1% | 0.7% |
| Less: Depreciation | 265 | 299 | 341 | 369 | 411 |
| EBIT | 1,962 | 418 | 2,645 | 2,406 | 2,383 |
| Growth % | -18.8% | -78.7% | 533.3% | -9.0% | -1.0% |
| Interest Paid | 114 | 160 | 146 | 63 | 63 |
| Non-operating Income | 110 | 66 | 33 | 50 | 50 |
| Extraordinary Income | -95 | -3 | -6 | 0 | 0 |
| Profit Before tax | 1,863 | 321 | 2,526 | 2,393 | 2,370 |
| Tax | 698 | 110 | 645 | 602 | 597 |
| Net Profit | 1,165 | 210 | 1,881 | 1,791 | 1,773 |
| Adjusted Profit | 1,260 | 213 | 1,887 | 1,791 | 1,773 |
| Reported Diluted EPS | 37.8 | 6.8 | 61.1 | 58.1 | 57.6 |
| Growth % | -20.2% | -81.9% | 793.9% | -4.8% | -1.0% |
| Adjusted Diluted EPS | 40.9 | 6.9 | 61.3 | 58.1 | 57.6 |
| Growth % | -13.7% | -83.1% | 784.4% | -5.1% | -1.0% |

Source: Company, BP Equities Research

| | Cash Flows State | ement | | | |
|---|------------------|-----------|-----------|-----------|-----------|
| YE March (INR. Mn) | FY19 | FY20 | FY21 | FY22E | FY23E |
| PAT | 1,164.8 | 210.4 | 1,881.1 | 1,790.8 | 1,773.4 |
| (Less)/Add: Extraordinary Income/Expense | 95.0 | 2.9 | 6.2 | 0.0 | 0.0 |
| Less: Non Operating Income | (110.2) | (65.6) | (33.3) | (50.0) | (50.0) |
| Add: Depreciation | 264.6 | 299.0 | 341.0 | 369.1 | 411.2 |
| Add: Interest Paid | 114.4 | 159.5 | 145.6 | 63.0 | 63.0 |
| Tax Adjustment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating Profit before Working Capital Changes | 1,528.6 | 606.3 | 2,340.6 | 2,172.9 | 2,197.6 |
| (Inc)/Dec in Current Assets | (803.8) | 978.6 | (381.1) | (771.5) | (47.5) |
| Inc/(Dec) in Current Liabilities | 750.6 | (126.6) | 378.9 | 2,397.8 | 111.2 |
| Changes in Inventory | (350.6) | 343.6 | (487.6) | (556.4) | (34.3) |
| Net Cash Generated From Operations | 1,124.8 | 1,802.0 | 1,850.7 | 3,242.7 | 2,227.0 |
| Cash Flow from Investing Activities | | | | | |
| (Inc)/Dec in Fixed Assets | 25.6 | (1,081.6) | (2,643.5) | (1,000.0) | (1,500.0) |
| (Inc)/Dec in Capital Work In Progress | (1,274.7) | (511.5) | 1,353.7 | 0.0 | 0.0 |
| (Inc)/Dec in Investment (Strategic) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| (Inc)/Dec in Investment (Others) | 31.2 | (45.1) | 35.9 | (31.4) | (34.5) |
| Add: Non Operating Income | 110.2 | 65.6 | 33.3 | 50.0 | 50.0 |
| (Inc)/Dec in Intangible Assets | (239.8) | (2.0) | 216.3 | 0.0 | 0.0 |
| Net Cash Flow from/(used in) Investing Activities | (1,347.5) | (1,574.5) | (1,004.3) | (981.4) | (1,484.5) |
| Cash Flow from Financing Activities | | | | | |
| Inc/(Dec) in Total Loans | 774.4 | 236.9 | (315.0) | 0.0 | 0.0 |
| Inc/(Dec) in Reserves & Surplus | (32.1) | (95.1) | 228.8 | 0.0 | 0.0 |
| Inc/(Dec) in Equity | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 |
| Dividend Paid | (123.2) | (61.6) | (231.0) | (231.0) | (231.0) |
| Less: Interest Paid | (114.4) | (159.5) | (145.6) | (63.0) | (63.0) |
| Adjustments | (153.1) | (38.5) | (0.0) | 0.0 | 0.0 |
| Exceptional Item | (95.0) | (2.9) | (6.2) | 0.0 | 0.0 |
| Net Cash Flow from Financing Activities | 256.7 | (120.7) | (469.0) | (293.9) | (293.9) |
| Net Inc/Dec in cash equivalents | 34.0 | 106.7 | 377.5 | 1,967.4 | 448.6 |
| Opening Balance | 217.3 | 251.3 | 358.0 | 735.5 | 2,702.9 |
| Closing Balance Cash and Cash Equivalents | 251.3 | 358.0 | 735.5 | 2,702.9 | 3,151.5 |

Source: Company, BP Equities Research



| | Balance Sheet | | | | |
|--|---------------|-------|--------|---------------|--------|
| YE March(INR. mn) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Liabilities | | | | | |
| Equity Capital | 308 | 308 | 308 | 308 | 308 |
| Reserves & Surplus | 5,979 | 6,033 | 7,912 | 9,472 | 11,014 |
| Equity | 6,287 | 6,341 | 8,220 | 9,780 | 11,322 |
| Net Worth | 6,287 | 6,341 | 8,220 | 9,780 | 11,322 |
| Minority Interest | | | | | |
| Others | 822 | 869 | 830 | 830 | 830 |
| Total Loans | 1,346 | 1,536 | 1,259 | 1,259 | 1,259 |
| Capital Employed | 8,455 | 8,746 | 10,310 | 11,869 | 13,412 |
| Assets | | | | | |
| Gross Block | 8,420 | 9,502 | 12,145 | 13,145 | 14,645 |
| Less: Depreciation | 4,528 | 4,789 | 5,130 | 5,499 | 5,910 |
| Net Block | 3,892 | 4,769 | 7,016 | 7, 647 | 8,735 |
| Capital WIP | 2,161 | 2,672 | 1,319 | 1,319 | 1,319 |
| Investments | 305 | 350 | 314 | 345 | 380 |
| Others - A | 434 | 436 | 220 | 220 | 220 |
| Current Assets | 404 | 430 | 220 | 220 | 220 |
| Inventories | 1,294 | 951 | 1,438 | 1,995 | 2,029 |
| Sundry Debtors | 1,828 | 1,433 | 1,987 | 2,756 | 2,804 |
| Cash and Bank Balance | 251 | 358 | 736 | 2,703 | 3,152 |
| Current Investments | 698 | 116 | 100 | 100 | 100 |
| Loans and Advances | 184 | 171 | 7 | 10 | 10 |
| Other Current Assets | 84 | 95 | 102 | 102 | 102 |
| Total Current Assets | 4,340 | 3,124 | 4,370 | 7,666 | 8,196 |
| Less: Current Liabilities & Provisions | , | • | , | • | , |
| Sundry Creditors | 2,300 | 1,996 | 2,397 | 4,527 | 4,605 |
| Provisions | 16 | 22 | 10 | 20 | 40 |
| Other Current Liabilities | 361 | 532 | 522 | 779 | 793 |
| Total Current Liabilities & Provisions | 2,676 | 2,550 | 2,928 | 5,326 | 5,437 |
| Capital Applied | 8,455 | 8,746 | 10,310 | 11,869 | 13,412 |

Source: Company, BP Equities Research

| | Key Ratios | | | | |
|-----------------------------|------------|---------|--------|--------|-------|
| YE March (INR. mn) | FY19 | FY20 | FY21 | FY22E | FY23E |
| Key Operating Ratios | | | | | |
| EBITDA Margin (%) | 17.1% | 6.8% | 26.6% | 17.8% | 17.6% |
| Tax / PBT (%) | 37.5% | 34.4% | 25.5% | 25.2% | 25.2% |
| Net Profit Margin (%) | 8.9% | 2.0% | 16.7% | 11.5% | 11.2% |
| RoE (%) | 21.8% | 3.4% | 25.9% | 19.9% | 16.8% |
| RoCE (%) | 30.8% | 5.6% | 30.2% | 23.0% | 19.9% |
| Current Ratio (x) | 1.6x | 1.2x | 1.5x | 1.4x | 1.5 |
| Dividend Payout (%) | 10.6% | 29.3% | 12.3% | 12.3% | 12.3% |
| Book Value Per Share (INR.) | 204.1 | 205.9 | 266.9 | 317.5 | 367.6 |
| Financial Leverage Ratios | | | | | |
| Debt/ Equity (x) | 0.2x | 0.2x | 0.2x | 0.1x | 0.11 |
| Interest Coverage (x) | 19.5x | 4.5x | 20.5x | 44.1x | 44.4 |
| Growth Indicators % | | | | | |
| Growth in Gross Block (%) | (0.3%) | 12.8% | 27.8% | 8.2% | 11.4% |
| Sales Growth (%) | 13.9% | (18.8%) | 6.1% | 38.7% | 1.7% |
| EBITDA Growth (%) | (16.7%) | (67.8%) | 316.7% | (7.1%) | 0.7% |
| Net Profit Growth (%) | (20.2%) | (81.9%) | 793.9% | (4.8%) | (1.0% |
| Diluted EPS Growth (%) | (20.2%) | (81.9%) | 793.9% | (4.8%) | (1.0% |
| Turnover Ratios | | | | | |
| Debtors Days | 51 | 49 | 65 | 65 | 65 |
| Creditors Days | 78 | 74 | 106 | 106 | 106 |
| Inventory Days | 36 | 33 | 47 | 47 | 47 |



Research Desk Tel: +91 22 61596406

Institutional Sales Desk Tel: +91 22 61596403/04/05

Disclaimer Appendix

Analyst (s) holding in the Stock: Nil

Analyst (s) Certification:

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001 Phone- +91 22 6159 6464 Fax-+91 22 6159 6160 Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building, Dalal street, Fort, Mumbai-400001

BP Wealth Management Pvt. Ltd. CIN No: U67190MH2005PTC154591

BP Equities Pvt. Ltd.

CIN No: U67120MH1997PTC107392